[
  {
    "year": "1998-2001*",
    "tx": "Alemtuzumab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD52-directed cytolytic antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Alitretinoin",
    "biomarker": "",
    "agentClass": "Retinoid",
    "drugTarget": "Vitamin A derivative; activates retinoid receptors PML-RARɑ",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Arsenic trioxide",
    "biomarker": "PML-RARɑ Fusion",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Chemotherapeutic agent; targets PML-RARɑ",
    "targetedTx": "N",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "1998-2001*",
    "tx": "Bexarotene",
    "biomarker": "",
    "agentClass": "Retinoid",
    "drugTarget": "Selective activator of retinoid X receptors (RXR)s",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Capecitabine",
    "biomarker": "",
    "agentClass": "Nucleoside metabolic inhibitor",
    "drugTarget": "Nucleoside metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Denileukin diftitox",
    "biomarker": "CD25+",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD25-directed cytotoxin",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "1998-2001*",
    "tx": "Epirubicin",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Anthracycline topoisomerase inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Exemestane",
    "biomarker": "ER+",
    "agentClass": "Hormone therapy",
    "drugTarget": "Aromatase inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "1998-2001*",
    "tx": "Gemtuzumab ozogamicin",
    "biomarker": "CD33+",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD33 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2018",
    "tx": "Lorlatinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include ALK and ROS1 among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "1998-2001*",
    "tx": "Temozolomide",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Alkylating agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Thalidomide",
    "biomarker": "",
    "agentClass": "Other Immunotherapy",
    "drugTarget": "Immunomodulatory drug",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Trastuzumab",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-HER2 (ERBB2) antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "1998-2001*",
    "tx": "Triptorelin",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Gonadotropin-releasing hormone (GnRH) agonist",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Valrubicin",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Anthracycline",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2002",
    "tx": "Fulvestrant",
    "biomarker": "HR+/ HER2-",
    "agentClass": "Hormone therapy",
    "drugTarget": "Selective estrogen receptor degrader (SERD)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2002",
    "tx": "Ibritumomab tiuxetan",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD20 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2002",
    "tx": "Oxaliplatin",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Alkylating agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2003",
    "tx": "Abarelix",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Gonadotropin-releasing hormone (GnRH) antagonist",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2003",
    "tx": "Bortezomib",
    "biomarker": "",
    "agentClass": "Proteasome inhibitors/protein synthesis inhibitor",
    "drugTarget": "Proteasome inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2003",
    "tx": "Gefitinib",
    "biomarker": "EGFR L858R, Exon 19 Deletions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR tyrosine kinase inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2003",
    "tx": "Tositumomab and Iodine I 131 Tositumomab",
    "biomarker": "CD20+",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD20 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2004",
    "tx": "Azacitidine",
    "biomarker": "",
    "agentClass": "Nucleoside metabolic inhibitor",
    "drugTarget": "Nucleoside metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2004",
    "tx": "Bevacizumab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-VEGF antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2004",
    "tx": "Cetuximab",
    "biomarker": "KRAS Wildtype and EGFR-expressing",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-EGFR antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2004",
    "tx": "Clofarabine",
    "biomarker": "",
    "agentClass": "Nucleoside metabolic inhibitor",
    "drugTarget": "Nucleoside metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2004",
    "tx": "Erlotinib",
    "biomarker": "EGFR L858R, Exon 19 Deletions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR tyrosine kinase inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2004",
    "tx": "Pemetrexed disodium",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Folate analog metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2005",
    "tx": "Nelarabine",
    "biomarker": "",
    "agentClass": "Nucleoside metabolic inhibitor",
    "drugTarget": "Nucleoside metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "1998-2001*",
    "tx": "Imatinib",
    "biomarker": "*Ph+ (BCR-ABL1 Fusion)\n*KIT+\n*PDGFRA, PDGFRB Fusions\n*PDGFB Fusions\n*FIP1L1-PDGFRA fusion",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include BCR-ABL, KIT, PDGFRA)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2019",
    "tx": "Pexidartinib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include CSF1R, KIT and FLT3)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2006",
    "tx": "Decitabine",
    "biomarker": "",
    "agentClass": "Nucleoside metabolic inhibitor",
    "drugTarget": "Nucleoside metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2006",
    "tx": "Lenalidomide",
    "biomarker": "",
    "agentClass": "Other Immunotherapy",
    "drugTarget": "Immunomodulatory drug",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2006",
    "tx": "Panitumumab",
    "biomarker": "KRAS and NRAS Wildtype and EGFR-expressing",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-EGFR antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2019",
    "tx": "Erdafitinib",
    "biomarker": "FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion, FGFR3 S249C, R248C, G370C, Y373C",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include FGFR1/2/3/4 among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2006",
    "tx": "Vorinostat",
    "biomarker": "",
    "agentClass": "HDAC inhibitor",
    "drugTarget": "Histone deacetylase (HDAC) inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2007",
    "tx": "Ixabepilone",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Microtubule inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2007",
    "tx": "Lapatinib",
    "biomarker": "HER2 Overexpression (ERBB2 Amplification)",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Dual tyrosine kinase inhibitor (targets EGFR and ERBB2)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Midostaurin",
    "biomarker": "FLT3 ITD Mutations, TKD Mutations I836 and D835",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include FLT3, VEGFR2, KIT and PDGFR)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2007",
    "tx": "Temsirolimus",
    "biomarker": "",
    "agentClass": "Large molecule inhibitor",
    "drugTarget": "mTOR inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2008",
    "tx": "Bendamustine hydrochloride",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Alkylating agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2008",
    "tx": "Degarelix",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Gonadotropin-releasing hormone (GnRH) antagonist",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2009",
    "tx": "Everolimus",
    "biomarker": "TSC1, TSC2 Oncogenic Mutations",
    "agentClass": "Large molecule inhibitor",
    "drugTarget": "mTOR inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2009",
    "tx": "Ofatumumab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD20 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2019",
    "tx": "Fedratinib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include JAK2 and FLT3)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2009",
    "tx": "Pralatrexate",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Folate analog metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2009",
    "tx": "Romidepsin",
    "biomarker": "",
    "agentClass": "HDAC inhibitor",
    "drugTarget": "Histone deacetylase (HDAC) inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2010",
    "tx": "Cabazitaxel",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Microtubule inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2010",
    "tx": "Eribulin",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Microtubule inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2010",
    "tx": "Sipuleucel-T",
    "biomarker": "",
    "agentClass": "Other Immunotherapy",
    "drugTarget": "Autologous cellular immunotherapy",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2011",
    "tx": "Abiraterone",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Antiandrogen; CYP17 inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2011",
    "tx": "Asparaginase erwinia chrysanthemi",
    "biomarker": "",
    "agentClass": "Other",
    "drugTarget": "Asparagine-specific enzyme",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2011",
    "tx": "Brentuximab vedotin",
    "biomarker": "CD30+",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD30-directed antibody-drug conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2020",
    "tx": "Avapritinib",
    "biomarker": "*PDGFRA Exon 18 Mutations\n*KIT D816",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include KIT D816V, PDGFRA, PDGFRA D842, KIT exon 11, 11/17 and 17 mutants)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2011",
    "tx": "Ipilimumab",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-CTLA-4 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2011",
    "tx": "Peginterferon alfa-2b",
    "biomarker": "",
    "agentClass": "Interferon/cytokine/chemokine",
    "drugTarget": "Alpha interferon",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2011",
    "tx": "Ruxolitinib",
    "biomarker": "",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "JAK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2019",
    "tx": "Entrectinib",
    "biomarker": "*NTRK1, NTRK2, NTRK3 Fusions\n*ROS1 Fusions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include NTRK1/2/3, ROS1 and ALK among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2011",
    "tx": "Vemurafenib",
    "biomarker": "BRAF V600",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "BRAF inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2012",
    "tx": "Aflibercept",
    "biomarker": "",
    "agentClass": "Other",
    "drugTarget": "VEGF inhibitor; VEGF-Trap",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2012",
    "tx": "Axitinib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "VEGFR1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "Umbralisib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include PI3Kδ and CK1ε among others)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Repotrectinib",
    "biomarker": "*ROS1 Fusions \n*NTRK Fusions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include ROS1 and NTRK1/2/3)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2012",
    "tx": "Carfilzomib",
    "biomarker": "",
    "agentClass": "Proteasome inhibitors/protein synthesis inhibitor",
    "drugTarget": "Proteasome inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2012",
    "tx": "Enzalutamide",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Antiandrogen; AR inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2012",
    "tx": "Omacetaxine mepesuccinate",
    "biomarker": "",
    "agentClass": "Proteasome inhibitors/protein synthesis inhibitor",
    "drugTarget": "Cephalotaxine ester and protein synthesis inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2012",
    "tx": "Pertuzumab + Trastuzumab",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Monoclonal antibody combination",
    "drugTarget": "Anti-HER2 (ERBB2) antibody + Anti-HER2 (ERBB2) antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2006",
    "tx": "Dasatinib",
    "biomarker": "Ph+ (BCR-ABL1 Fusion)",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include SRC, BCR-ABL1, KIT and PDGFRβ among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2005",
    "tx": "Sorafenib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include VEGFR1/2/3, BRAF, KIT, FLT3 and PDGFRβ among others)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2012",
    "tx": "Vismodegib",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "SMO inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2013",
    "tx": "Ado-trastuzumab emtansine",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "HER2 (ERBB2)-directed antibody and microtubule inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2013",
    "tx": "Afatinib",
    "biomarker": "EGFR L858R, G719X, L861Q, S768I, Exon 19 Deletions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR tyrosine kinase inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2013",
    "tx": "Dabrafenib",
    "biomarker": "BRAF V600E/K",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "BRAF inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2013",
    "tx": "Ibrutinib",
    "biomarker": "17p del",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "BTK inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2013",
    "tx": "Obinutuzumab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD20 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2013",
    "tx": "Pomalidomide",
    "biomarker": "",
    "agentClass": "Other Immunotherapy",
    "drugTarget": "Immunomodulatory drug; Thalidomide analog",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2013",
    "tx": "Ra 223 dichloride",
    "biomarker": "",
    "agentClass": "Radiotherapy",
    "drugTarget": "Alpha particle-emitting radioactive therapeutic agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2013",
    "tx": "Trametinib",
    "biomarker": "BRAF V600E/K",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2014",
    "tx": "Belinostat",
    "biomarker": "",
    "agentClass": "HDAC inhibitor",
    "drugTarget": "Histone deacetylase (HDAC) inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2014",
    "tx": "Blinatumomab",
    "biomarker": "CD19+",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific CD19-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2014",
    "tx": "Ceritinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "ALK inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2014",
    "tx": "Dabrafenib + Trametinib",
    "biomarker": "BRAF V600E/K",
    "agentClass": "Small molecule kinase inhibitor combination",
    "drugTarget": "BRAF inhibitor + MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2014",
    "tx": "Idelalisib",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PIK3Kδ inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2014",
    "tx": "Lanreotide",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Somatostatin analog",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2014",
    "tx": "Mercaptopurine",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Purine analog; interferes with nucleic acid synthesis",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2014",
    "tx": "Nivolumab",
    "biomarker": "MSI-H",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2014",
    "tx": "Olaparib",
    "biomarker": "*BRCA1, BRCA2 Oncogenic Mutations  \n*ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54 Oncogenic Mutations",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PARP inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2014",
    "tx": "Pembrolizumab",
    "biomarker": "*MSI-H or dMMR\n*TMB-H\n*PD-L1-expressing\n*pMMR",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2014",
    "tx": "Ramucirumab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-VEGFR2 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2014",
    "tx": "Siltuximab",
    "biomarker": "",
    "agentClass": "Interferon/cytokine/chemokine",
    "drugTarget": "Interleukin-6 (IL-6) antagonist",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Alectinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "ALK inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2015",
    "tx": "Vemurafenib + Cobimetinib ",
    "biomarker": "BRAF V600E/K",
    "agentClass": "Small molecule kinase inhibitor combination",
    "drugTarget": "BRAF inhibitor + MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2015",
    "tx": "Daratumumab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD38 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Dinutuximab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-GD2 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Elotuzumab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-SLAMF7 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Ipilimumab + Nivolumab",
    "biomarker": "*MSI-H or dMMR\n*PD-L1-expressing",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-CTLA-4 antibody + Anti-PD1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2015",
    "tx": "Ixazomib",
    "biomarker": "",
    "agentClass": "Proteasome inhibitors/protein synthesis inhibitor",
    "drugTarget": "Proteasome inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "Tivozanib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted kinase inhibitor (targets include VEGFR1/2/3, KIT and PDGFRβ)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Necitumumab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-EGFR antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Osimertinib",
    "biomarker": "EGFR T790M, L858R, Exon 19 Deletions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR tyrosine kinase inhibitor with T790M",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2015",
    "tx": "Palbociclib",
    "biomarker": "HR+/ HER2-",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "CDK4/6 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2015",
    "tx": "Panobinostat",
    "biomarker": "",
    "agentClass": "HDAC inhibitor",
    "drugTarget": "Histone deacetylase (HDAC) inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Sonidegib",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "SMO inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Talimogene laherparepvec",
    "biomarker": "",
    "agentClass": "Other",
    "drugTarget": "Oncolytic viral therapy",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Trabectedin",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Alkylating agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Trifluridine/ tipiracil",
    "biomarker": "",
    "agentClass": "Nucleoside metabolic inhibitor",
    "drugTarget": "Nucleoside metabolic inhibitor/Thymidine phosphorylase inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2016",
    "tx": "Atezolizumab",
    "biomarker": "PD-L1-expressing",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-L1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2016",
    "tx": "Olaratumab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-PDGFRɑ antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2016",
    "tx": "Rucaparib",
    "biomarker": "BRCA1, BRCA2 Oncogenic Mutations",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PARP inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2016",
    "tx": "Venetoclax",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "BCL-2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2017",
    "tx": "Abemaciclib",
    "biomarker": "HR+/ HER2-",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "CDK4/6 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2017",
    "tx": "Acalabrutinib",
    "biomarker": "",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "BTK inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2017",
    "tx": "Avelumab",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PDL-1 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2017",
    "tx": "Axicabtagene ciloleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (CD-19 directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2017",
    "tx": "Brigatinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "ALK inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Copanlisib",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PIK3K inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2017",
    "tx": "Daunorubicin + Cytarabine",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Anthracycline topoisomerase inhibitor + nucleoside metabolic inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2017",
    "tx": "Durvalumab",
    "biomarker": "dMMR",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PDL-1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2017",
    "tx": "Enasidenib",
    "biomarker": "IDH2 R140Q/L/G/W, R172G/K/M/S/W",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "IDH2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Inotuzumab Ozogamicin",
    "biomarker": "CD22+",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD22-directed antibody-drug conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2011",
    "tx": "Crizotinib",
    "biomarker": "*ALK+ (ALK Fusions)\n*ROS1+ (ROS1 Fusions)",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted receptor tyrosine kinase inhibitor (targets include ALK, ROS1 and MET)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Neratinib",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR//HER2 (ERBB2)/HER4 (ERBB4) inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Niraparib",
    "biomarker": "BRCA1, BRCA2 Oncogenic Mutations",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PARP inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Ribociclib",
    "biomarker": "HR+/ HER2-",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "CDK4/6 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2017",
    "tx": "Tisagenlecleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (CD-19 directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Apalutamide",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Antiandrogen; AR inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Encorafenib + Binimetinib",
    "biomarker": "BRAF V600E/K",
    "agentClass": "Small molecule kinase inhibitor combination",
    "drugTarget": "BRAF inhibitor + MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2018",
    "tx": "Calaspargase pegol",
    "biomarker": "",
    "agentClass": "Other",
    "drugTarget": "Asparagine specific-enzyme",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Cemiplimab",
    "biomarker": "PD-L1-expressing",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2018",
    "tx": "Dacomitinib",
    "biomarker": "EGFR L858R, Exon 19 Deletions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR tyrosine kinase inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2018",
    "tx": "Duvelisib",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PI3Kδ/ᵞ inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2011",
    "tx": "Vandetanib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR, EGFR and RET)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Glasdegib",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "SMO inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Iobenguane",
    "biomarker": "",
    "agentClass": "Radiotherapy",
    "drugTarget": "Radioactive therapeutic agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Ivosidenib",
    "biomarker": "IDH1 R132C/G/H/L/S",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "IDH1 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2018",
    "tx": "Larotrectinib",
    "biomarker": "NTRK1, NTRK2, NTRK3 Fusions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "NTRK1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2012",
    "tx": "Cabozantinib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR1/2/3, AXL, KIT, RET and ROS1 among others)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Lutetium Lu 177 dotatate",
    "biomarker": "Somatostatin Receptor",
    "agentClass": "Hormone therapy",
    "drugTarget": "Radiolabeled somatostatin analog",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2018",
    "tx": "Mogamulizumab",
    "biomarker": "",
    "agentClass": "Interferon/cytokine/chemokine",
    "drugTarget": "Anti-CCR4 antibody",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Moxetumomab pasudotox",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD22-directed antibody-drug conjugate",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Tagraxofusp",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD123-directed cytotoxin",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2018",
    "tx": "Talazoparib",
    "biomarker": "*BRCA1, BRCA2 Oncogenic Mutations\n*ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, RAD51C\nOncogenic Mutations",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "PARP inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2019",
    "tx": "Alpelisib + Fulvestrant",
    "biomarker": "PIK3CA E545G, Q546E, E545A, H1047R, C420R, H1047Y, Q546R, H1047L, E542K, E545D, E545K",
    "agentClass": "Small molecule inhibitor and hormone therapy combination",
    "drugTarget": "α-specific PI3K inhibitor + selective estrogen receptor degrader (SERD)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2019",
    "tx": "Darolutamide",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Antiandrogen; AR inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2019",
    "tx": "Enfortumab vedotin",
    "biomarker": "",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "Nectin-4-directed antibody and microtubule inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2015",
    "tx": "Lenvatinib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR1/2/3, FGFR1/2/3/4, KIT, RET and PDGFRβ among others)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2006",
    "tx": "Sunitinib",
    "biomarker": "KIT+",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR1/2/3, KIT, FLT3, CSF1R and PDGFRɑ/β among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2012",
    "tx": "Bosutinib",
    "biomarker": "Ph+ (BCR-ABL1 Fusion)",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted tyrosine kinase inhibitor (targets include BCR-ABL1 and SRC family kinases)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2007",
    "tx": "Nilotinib",
    "biomarker": "Ph+ (BCR-ABL1 Fusion)",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted tyrosine kinase inhibitor (targets include BCR-ABL1, PDGFR and KIT among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2019",
    "tx": "Polatuzumab vedotin",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD79b-directed antibody-drug conjugate",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2019",
    "tx": "Selinexor",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "Nuclear export inhibitor (XPO1 inhibitor)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2019",
    "tx": "Trastuzumab deruxtecan",
    "biomarker": "*HER2+ (ERBB2 Amplification)\n*HER2-low\n*ERBB2 Oncogenic Mutations \n*HR+/HER2-low or HER2-ultralow",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "HER2 (ERBB2)-directed antibody and topoisomerase inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2019",
    "tx": "Zanubrutinib",
    "biomarker": "",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "BTK inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Atezolizumab + Vemurafenib + Cobimetinib",
    "biomarker": "BRAF V600",
    "agentClass": "Small molecule inhibitor and immune checkpoint inhibitor combination",
    "drugTarget": "Anti-PDL-1 antibody + BRAF inhibitor + MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2012",
    "tx": "Ponatinib",
    "biomarker": "Ph+ (BCR-ABL1 Fusion) or\nABL1 T315I",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted tyrosine kinase inhibitor (targets include BCR-ABL1, VEGFR, PDGFR, FGFR and SRC family members among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Belantamab mafodotin",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "BCMA-directed antibody-drug conjugate",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Brexucabtagene autoleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (CD-19 directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Capmatinib",
    "biomarker": "MET Exon 14 Skipping Mutations",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "MET inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Decitabine + Cedazuridine (INQOVI)",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Nucleoside metabolic inhibitor + cytidine deaminase inhibitor",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Encorafenib + Cetuximab",
    "biomarker": "BRAF V600E",
    "agentClass": "Small molecule inhibitor and monoclonal antibody combination",
    "drugTarget": "BRAF inhibitor + Anti-EGFR antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Isatuximab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "Anti-CD38 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Lurbinectedin",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Alkylating agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Margetuximab",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-HER2 (ERBB2) antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Naxitamab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-GD2 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Pemigatinib",
    "biomarker": "*FGFR2 Fusions\n*FGFR1 Fusions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "FGFR1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Pralsetinib",
    "biomarker": "RET Fusions and Oncogenic Mutations",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "RET inhibitor (also reported to inhibit other kinases including DDR1, NTRK3, FLT3 and FGFR1/2 among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Relugolix",
    "biomarker": "",
    "agentClass": "Hormone therapy",
    "drugTarget": "Gonadotropin-releasing hormone (GnRH) antagonist",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Ripretinib",
    "biomarker": "KIT/PDGFRA inhibitor",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "KIT/PDGFRA D816",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Sacituzumab govitecan",
    "biomarker": "HR+/HER2-",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "TROP2-directed antibody and topoisomerase inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2020",
    "tx": "Selpercatinib",
    "biomarker": "RET Fusions and Oncogenic Mutations",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "RET inhibitor (also reported to inhibit other kinases including VEGFR1/2/3 and FGFR1/2/3)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Selumetinib",
    "biomarker": "NF1 Oncogenic Mutations",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Tafasitamab",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD19-directed cytolytic monoclonal antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2020",
    "tx": "Tazemetostat",
    "biomarker": "*EZH2 Y646F, A692V, Y646C, Y646S, Y646N, Y646H, A682G\n*SMARCB1 Deletion",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "EZH2 inhibitor (methyltransferase inhibitor)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2020",
    "tx": "Tucatinib + Trastuzumab",
    "biomarker": "*HER2+ (ERBB2 Amplifiaction)\n*KRAS and NRAS Wildtype and HER2+ (ERBB2 Amplification)",
    "agentClass": "Small molecule inhibitor and monoclonal antibody combination",
    "drugTarget": "HER2 (ERBB2) inhibitor + Anti-HER2 (ERBB2) antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Amivantamab",
    "biomarker": "*EGFR Exon 20 Insertions \n*EGFR Exon 19 Deletions, L858R",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "EGFR-MET bispecific antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Asciminib",
    "biomarker": "Ph+ (BCR-ABL1 Fusion)\nor ABL1 T315I",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "ABL/BCR-ABL1 tyrosine kinase inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Belzutifan",
    "biomarker": "VHL Oncogenic Mutations",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "HIF-2ɑ inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Dostarlimab",
    "biomarker": "*dMMR                                                     *dMMR or MSI-H",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Idecabtagene vicleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (BCMA-directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "Infigratinib",
    "biomarker": "FGFR2 Fusions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "FGFR1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Lisocabtagene maraleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (CD-19 directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "loncastuximab tesirine",
    "biomarker": "",
    "agentClass": "Hematopoietic protein binding antibody, ADC or cytotoxin",
    "drugTarget": "CD19-directed antibody-drug conjugate",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "Melphalan flufenamide",
    "biomarker": "",
    "agentClass": "Cytotoxic chemotherapy",
    "drugTarget": "Alkylating agent",
    "targetedTx": "N",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "Mobocertinib",
    "biomarker": "EGFR Exon 20 Insertions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "EGFR Exon 20 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Sirolimus",
    "biomarker": "",
    "agentClass": "Large molecule inhibitor",
    "drugTarget": "mTOR inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2021",
    "tx": "Sotorasib",
    "biomarker": "KRAS G12C",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "KRAS G12C inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Tepotinib",
    "biomarker": "MET Exon 14 Skipping Mutations",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "MET inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Tisotumab vedotin",
    "biomarker": "",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "Tissue factor-directed antibody microtubule inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2012",
    "tx": "Regorafenib",
    "biomarker": "KIT+",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted tyrosine kinase inhibitor (targets include KIT, RET, VEGFR1/2/3, FGFR1/2, PDGFRβ among others)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2021",
    "tx": "Trastuzumab + Pembrolizumab",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Monoclonal antibody and immune checkpoint inhibitor combination",
    "drugTarget": "Anti-HER2 (ERBB2) antibody + Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2018",
    "tx": "Gilteritinib",
    "biomarker": "FLT3 ITD Mutations, TKD Mutations I836 and D835",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "Multi-targeted tyrosine kinase inhibitor (targets include mutant and WT FLT3, AXL and ALK)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2022",
    "tx": "Adagrasib",
    "biomarker": "KRAS G12C",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "KRAS G12C inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2022",
    "tx": "Ciltacabtagene autoleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (BCMA-directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2022",
    "tx": "Futibatinib",
    "biomarker": "FGFR2 Fusions",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "FGFR1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2022",
    "tx": "Mirvetuximab soravtansine",
    "biomarker": "FRɑ",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "Folate receptor alpha-directed antibody microtubule inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2022",
    "tx": "Mosunetuzumab",
    "biomarker": "",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific CD20-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2022",
    "tx": "Nadofaragene firadenovec",
    "biomarker": "",
    "agentClass": "Gene therapy",
    "drugTarget": "Adenoviral vector-based gene therapy carrying IFNɑ2b",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2022",
    "tx": "Nivolumab + Relatlimab (Opdualag)",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-1 antibody + Anti-LAG-3 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2022",
    "tx": "Olutasidenib",
    "biomarker": "IDH1 R132C/G/H/L/S",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "IDH1 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2022",
    "tx": "Pluvicto",
    "biomarker": "PSMA+",
    "agentClass": "Radiotherapy",
    "drugTarget": "Radioligand therapeutic agent",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2022",
    "tx": "Tebentafusp",
    "biomarker": "HLA-A*02:01-positivity",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific gp100 peptide-HLA-A*02:01-directed T-cell receptor CD3 T cell engager",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2022",
    "tx": "Teclistamab",
    "biomarker": "",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific BCMA-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2022",
    "tx": "Tremelimumab",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-CTLA-4 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Capivasertib",
    "biomarker": "PIK3CA, AKT1 or PTEN Oncogenic Mutations and HR+/HER2-",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "AKT1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2023",
    "tx": "Elacestrant",
    "biomarker": "ESR1 Ligand-binding domain missense mutations and\nER+/HER2-",
    "agentClass": "Hormone therapy",
    "drugTarget": "Selective estrogen receptor degrader (SERD)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2023",
    "tx": "Elranatamab",
    "biomarker": "",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific BCMA-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Enfortumab vedotin + Pembrolizumab",
    "biomarker": "",
    "agentClass": "Antibody drug conjugate and immune checkpoint inhibitor combination ",
    "drugTarget": "Nectin-4-directed antibody and microtubule inhibitor conjugate + Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Epcoritamab ",
    "biomarker": "",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific CD20-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Fruquintinib",
    "biomarker": "",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "VEGFR1/2/3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Glofitamab",
    "biomarker": "",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "CD20-CD3 bispecific antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Pirtobrutinib",
    "biomarker": "",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "BTK inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Quizartinib",
    "biomarker": "FLT3 ITD Mutations",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "FLT3 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2009",
    "tx": "Pazopanib",
    "biomarker": "",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted tyrosine kinase inhibitor (targets include VEGFR1/2/3, PDGFRɑ/β, KIT, FGFR1/3 among others)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Retifanlimab",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Talquetamab",
    "biomarker": "",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific GPRC5D-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Toripalimab",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2023",
    "tx": "Eflornithine",
    "biomarker": "",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "Ornithine decarboxylase inhibitor ",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Lifileucel ",
    "biomarker": "",
    "agentClass": "Other Immunotherapy",
    "drugTarget": "Tumor-infiltrating lymphocyte therapy",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Nogapendekin alfa inbakicept",
    "biomarker": "",
    "agentClass": "Other Immunotherapy",
    "drugTarget": "Interleukin-15 (IL-15) antagonist",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Tovorafenib",
    "biomarker": "BRAF Fusions, BRAF Rearrangement, BRAF V600 ",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "RAF inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Tarlatamab",
    "biomarker": "",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific DLL3-directed CD3 T-cell engager",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Imetelstat",
    "biomarker": "",
    "agentClass": "Telomerase inhibitor",
    "drugTarget": "Telomerase template antagonist",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Afamitresgene autoleucel",
    "biomarker": "HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and MAGE-A4 antigen positive",
    "agentClass": "T cell receptor (TCR) therapy",
    "drugTarget": "MAGE-A4-directed TCR therapy",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2024",
    "tx": "Vorasidenib",
    "biomarker": "IDH1 R132H/C/G/S/L, IDH2 R172K/M/W/S/G",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "IDH1/IDH2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Lazertinib + Amivantamab",
    "biomarker": "EGFR L858R, Exon 19 Deletions",
    "agentClass": "Small molecule kinase inhibitor and monoclonal antibody combination",
    "drugTarget": "EGFR tyrosine kinase inhibitor + EGFR-MET bispecific antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Inavolisib + Fulvestrant + Palbociclib",
    "biomarker": "PIK3CA Oncogenic Mutations, HR+/HER2-",
    "agentClass": "Small molecule inhibitor and hormone therapy combination",
    "drugTarget": "α-specific PI3K inhibitor + selective estrogen receptor degrader + CDK4/6 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Adagrasib + Cetuximab",
    "biomarker": "KRAS G12C",
    "agentClass": "Small molecule inhibitor and monoclonal antibody combination",
    "drugTarget": "KRAS G12C inhibitor + Anti-EGFR antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Zolbetuximab",
    "biomarker": "HER2- and CLDN18.2+",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "CDLN18.2-directed cytolytic antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2024",
    "tx": "Obecabtagene autoleucel",
    "biomarker": "",
    "agentClass": "CAR T-cell therapy",
    "drugTarget": "CAR T-cell therapy (CD19-directed)",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Revumenib",
    "biomarker": "KMT2A Rearrangement",
    "agentClass": "Small molecule inhibitor",
    "drugTarget": "Menin inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Zanidatamab",
    "biomarker": "HER2+ (ERBB2 Amplification)",
    "agentClass": "Monoclonal antibody",
    "drugTarget": "Anti-HER2 (ERBB2) antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Zenocutuzumab",
    "biomarker": "NRG1 Fusion",
    "agentClass": "Bispecific T-cell engager",
    "drugTarget": "Bispecific HER2/HER3-directed T-cell engager",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2024",
    "tx": "Cosibelimab",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-L1 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2024",
    "tx": "Ensartinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "agentClass": "Multikinase inhibitor",
    "drugTarget": "Multi-targeted receptor tyrosine kinase inhibitor (targets include ALK, ROS1 and MET)",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2025",
    "tx": "Sotorasib + Panitumumab",
    "biomarker": "KRAS G12C",
    "agentClass": "Small molecule inhibitor and monoclonal antibody combination",
    "drugTarget": "KRAS G12C inhibitor + Anti-EGFR antibody",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2025",
    "tx": "Datopotamab deruxtecan",
    "biomarker": "HR+/HER2-",
    "agentClass": "Antibody drug conjugate",
    "drugTarget": "TROP2-directed antibody and topoisomerase inhibitor conjugate",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "N"
  },
  {
    "year": "2025",
    "tx": "Mirdametinib",
    "biomarker": "NF1 Oncogenic Mutations",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "MEK1/2 inhibitor",
    "targetedTx": "Y",
    "pxTx": "Y",
    "ngsTest": "Y"
  },
  {
    "year": "2025",
    "tx": "Vimseltinib",
    "biomarker": "",
    "agentClass": "Small molecule kinase inhibitor",
    "drugTarget": "CSF1R inhibitor",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  },
  {
    "year": "2025",
    "tx": "Penpulimab + Cisplatin or Carboplatin + Gemcitabine",
    "biomarker": "",
    "agentClass": "Immune checkpoint inhibitor",
    "drugTarget": "Anti-PD-1 antibody",
    "targetedTx": "Y",
    "pxTx": "N",
    "ngsTest": "NA"
  }
]
